GlassScriptPhysician profile
Mark Darryl Watkins
NPI 1780616664
$697.64
in general payments reported to CMS, 2019-2025
8 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $113 · 2020: $44.84 · 2021: $231 · 2022: $308.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $308.35 | 2022 | |
| Welch Allyn | $192.72 | 2021 | |
| Glaxosmithkline, LLC. | $86.65 | 2019-2021 | |
| Ironshore Pharmaceuticals INC. | $49.98 | 2019-2020 | |
| Viiv Healthcare Company | $22.90 | 2021 | |
| Shire North American Group INC | $13.96 | 2019 | |
| Pfizer INC. | $12.23 | 2019 | |
| Tris Pharma INC | $10.85 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Watkins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.